Unknown Timing of Lovenox Generics Complicates Sanofi-Aventis' Outlook
Executive Summary
LONDON - Sanofi-Aventis CEO Chris Viehbacher appeared uncomfortable discussing the expected timing of generic competition to Lovenox (enoxaparin) during a Feb. 10 earnings call
You may also be interested in...
Roche/Ipsen's Suspended Taspoglutide Could Be Another Diabetes Casualty
Roche's decision to halt dosing in a trial of the GLP-1 receptor agonist taspoglutide following an announcement of a major development delay illustrates the intensively competitive nature of the diabetes market
Roche/Ipsen's Suspended Taspoglutide Could Be Another Diabetes Casualty
Roche's decision to halt dosing in a trial of the GLP-1 receptor agonist taspoglutide following an announcement of a major development delay illustrates the intensively competitive nature of the diabetes market
Under Pressure: Sanofi's Strategy Will Be Tested By Generic Lovenox Approval
Ahead of the big pharma's earnings call July 29, Sanofi-Aventis is under renewed pressure with Momenta and partner Sandoz promising a swift launch of their newly approved generic version of Lovenox.